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Abstract
Background: Self-tests are those where an individual can obtain a result without recourse to a
health professional, by getting a result immediately or by sending a sample to a laboratory that
returns the result directly. Self-tests can be diagnostic, for disease monitoring, or both. There are
currently tests for more than 20 different conditions available to the UK public, and self-testing is
marketed as a way of alerting people to serious health problems so they can seek medical help.
Almost nothing is known about the extent to which people self-test for cancer or why they do this.
Self-tests for cancer could alter perceptions of risk and health behaviour, cause psychological
morbidity and have a significant impact on the demand for healthcare. This study aims to gain an
understanding of the frequency of self-testing for cancer and characteristics of users.
Methods: Cross-sectional survey. Adults registered in participating general practices in the West
Midlands Region, will be asked to complete a questionnaire that will collect socio-demographic
information and basic data regarding previous and potential future use of self-test kits. The only
exclusions will be people who the GP feels it would be inappropriate to send a questionnaire, for
example because they are unable to give informed consent. Freepost envelopes will be included
and non-responders will receive one reminder. Standardised prevalence rates will be estimated.
Discussion: Cancer related self-tests, currently available from pharmacies or over the Internet,
include faecal occult blood tests (related to bowel cancer), prostate specific antigen tests (related
to prostate cancer), breast cancer kits (self examination guide) and haematuria tests (related to
urinary tract cancers). The effect of an increase in self-testing for cancer is unknown but may be
considerable: it may affect the delivery of population based screening programmes; empower
patients or cause unnecessary anxiety; reduce costs on existing healthcare services or increase
demand to investigate patients with positive test results. It is important that more is known about
the characteristics of those who are using self-tests if we are to determine the potential impact on
health services and the public.
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Background
Self-tests are those where an individual can obtain a result
without recourse to a health professional: by getting a
result immediately (e.g. most prostate specific antigen
(PSA) and faecal occult blood (FOB) tests), or by sending
a sample to a laboratory that returns the result directly to
the individual (e.g. some chlamydia tests). Self-tests can
be diagnostic (e.g. urine tests for pregnancy), for disease
monitoring (e.g. blood pressure), or both (e.g. PSA tests).
There are currently tests for more than 20 different condi-
tions available to the UK public [1].
A number of reports have expressed concern about the
development of self-testing [2,3]. Potential problems
highlighted include: lack of professional support when
receiving bad news; lack of expertise in interpreting results
and action needed; unreliable results generating false
security or anxiety; that individuals may be forced to take
tests by people other than health professionals (e.g.
employers); the potential break-down of public health
surveillance; that commercially driven test development
may lead to demands for further testing or treatment
which the NHS is unable to meet. Much coverage of self-
testing in the press is also negative, warning of the unreli-
ability of tests and dangers of misunderstanding medical
information [4-7]. However, such reports do not seem to
have deterred users. Market research reports that "almost
six in ten Britons diagnose themselves at home with self-
testing equipment instead of going to the doctor",
although this does include thermometers [8]. Sales of self-
testing equipment are reported to have increased dramat-
ically: almost £54.3 m was spent on self-diagnostic prod-
ucts in 2002, a 32% growth since 1998 [9], and it has been
predicted that this will rise to over £60 m by 2007 [8].
Market surveys in the US indicate at least 25% of all med-
ical tests are conducted outside the hospital laboratory
and predict that by 2008 up to 45% of testing will be
either near patient or self-testing [10]. Revenue from the
self-testing market in the US doubled from $1.19 billion
in 1994 to $2.34 billion in 2000 and is anticipated to con-
tinue to grow. Long waits to see a GP and an increasingly
health-conscious population are among the factors
thought to contribute to the increased sales [8]. Some
areas are growing fast, particularly the use of rapid manual
or self-test kits [11].
Reasons for using self-tests may include: tests not being
available from a doctor (e.g. PSA tests to young men);
convenience; privacy; not wanting to bother doctors or
use NHS resources; dissatisfaction with, or mistrust of
doctors and/or medicine. In the UK, NHS Direct and
drop-in health centres aim to increase access to health
services and health information [12]. Such initiatives,
together with interventions aiming to redefine patients as
consumers, the increased availability of over the counter
medication, and funding pressures for health services,
have encouraged the development of a self-care culture.
People are taking more responsibility for their own health
and adopting more consumerist attitudes to health care
[13-15]. Self-testing may be part of this. Also, such test
results may empower people within a consultation with
their doctor, as has been seen in the use of Internet
resources [16].
Self-testing is marketed as a valuable way of alerting peo-
ple to serious health problems so they can seek medical
help [17]. Traditionally diagnosis, decision-making and
definitions of illness occur within a health service [18].
Having test results in isolation (e.g. slightly raised PSA lev-
els) without an assessment of signs and symptoms may
result in inappropriate labelling as a 'patient' [19] and
increase perceived risk. Self-testing may have beneficial
psychological effects (true negatives), but it could also
impact on the delivery of population based screening pro-
grammes, increase demands on health care services
(investigation and treatment of positive tests), lead to
false re-assurance (false negative tests) or raised anxiety,
and alter health behaviour/perceptions of risk. There is
some evidence that GPs feel that they are increasingly con-
sulted by the 'worried well', that their prescribing behav-
iour is affected by patient demand, and that they are
pressured by their role as gatekeepers to specialist services
[20-22], and increased self-testing may exacerbate this sit-
uation.
No systematic reviews relating to self-testing generally or
self-testing for cancer have been identified. The only UK
surveys addressing the issue of self-testing state that
18.3% and 24.9% of people reported that they would pre-
fer self-testing to testing by a doctor and a pharmacist
respectively [23], and that 32% of people had bought a
self-test kit (although this did include pregnancy tests)
[24]. Although other work is ongoing [25], there is cur-
rently a lack of published research examining the impact
of self-testing on individuals or on the healthcare system.
The literature that does exist has limitations; it tends to
concentrate on efficacy and reliability [26,27], has been
carried out in different health cultures in the US or Europe
[28], or is based on opinion only without empirical data
[29]. There has been research in areas which may be rele-
vant to self-testing for cancer, for example attendance for
routine screening, self examination and use of over the
counter medication [30-33]. Such behaviours have been
associated with socio-economic status, age, gender, eth-
nicity, and level of trust of the medical profession
[32,34,35]. The relevance of these factors to self-testing for
cancer may depend on whether self-testing is used to
inform choice and complement standard care, or to chal-
lenge standard care.BMC Cancer 2006, 6:215 http://www.biomedcentral.com/1471-2407/6/215
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A variety of cancer related self-tests are available to buy by
members of the UK public, including tests for faecal occult
blood [36], prostate specific antigen [37], haematuria
[38], serum α-Fetoprotein and serum carcinoembryonic
antigen (CEA) [39], and breast cancer self-examination
kits [40]. Cancer related self-tests are not only widely
available but also relatively inexpensive, costs range from
less than £1 for an FOB test to £25 for devices to feel for
breast irregularities.
Advertising directly to the public for genetic tests for the
familial breast cancer genes BRCA1 and BRCA2 began in
the USA in 2001 [41]. Advertising cancer genetic services
increases demand for products that are likely to be of little
benefit outside high-risk families [42]. A number of com-
panies have promoted the idea of "predictive medicine"
(using genetic tests to predict the chances that someone
will get serious illnesses like cancer), and then offering
either lifestyle advice or medication [43,44].
Health Which (December 2002), the press (Guardian
November 4 2003 and February 6 2004) and BACUP [45]
have advertised the availability of cancer self-test kits from
high street chemists. Should Internet sales be shown to be
profitable, a wider range of cancer self-test kits is likely to
become available from pharmacies. The possible range of
new products related to the prevention, diagnosis and
treatment of cancer is wide, and potential new develop-
ments include a saliva test for breast cancer [46], bladder
cancer home tests (currently prescription only) [47], ultra-
violet monitors to avoid skin cancer [48], and kits for test-
ing your response to alternative cancer treatments [49].
Cancer related self-testing may develop to include tests for
the early diagnosis of cancers at more sites, the genetic
determinants of disease [50] and drug effectiveness [51].
The characteristics of those who participate in population
based screening and the impact of screening programmes
(i.e. costs and benefits to the NHS and participants) have
received considerable attention [52]. Almost nothing is
known about the extent to which people screen them-
selves for cancer or why they do this. Self-tests for cancer
could alter perceptions of risk and health behaviour, cause
psychological morbidity and have a significant impact on
the demand for healthcare. Furthermore, they may impact
on the cost-effectiveness of population-based screening. It
is essential that we gain an understanding of the frequency
of self-testing for cancer, characteristics of users and the
effects of test results on both users and the health service.
It is important that we obtain this information before self-
testing for cancer becomes more widely available, to be
able to determine the potential impact on both the public
and health services.
Study aims
To estimate the prevalence of cancer-related self-testing
use and compare characteristics of users, non-users and
potential users of self-tests for cancer.
Methods
Study design: community based survey
Study population
All adults, over the age of 18, selected from the lists of par-
ticipating general practices in the West Midlands. The only
exclusions will be people who the GP feels it would be
inappropriate to send a questionnaire.
Recruitment of practices
three to five practices, stratified by Townsend score (cen-
sus based indicator of deprivation) will be recruited. Lists
of eligible persons will be generated from practice regis-
ters. These lists will be scrutinised by general practitioners,
who will remove all patients where it is deemed inappro-
priate for a questionnaire to be sent, for example because
of recent bereavement, terminal illness or unable to give
informed consent.
Methods of data collection
Reply-paid postal questionnaire survey of 5000 people
selected from the lists of participating practices. Freepost
envelopes will be included and non-responders will
receive one reminder [53]. This short questionnaire will
collect socio-demographic information and basic data
regarding previous and potential future use of self-test
kits. To minimise response bias, we have incorporated
questions relating to self-testing for a range of conditions,
rather than just cancer.
Justification of sample size
Sixty percent of the population have been reported to use
self-test kits [8], but the proportion that has used a self-
test kit for cancer is unknown. Conservatively assuming
that 1% of people have used a cancer-related self-test and
a response rate of 47%, mailing 5000 people will allow
estimation of the prevalence of the use of self-tests with +-
4% precision and 95% confidence [54].
Based on a response rate of 40%, which is less than other
large prevalence surveys [55], the questionnaire will be
sent to 10500 people. Assuming an average list size of
4500 people, 75% of whom are 18 years or older [56], and
5% of whom meet the exclusion criteria, it would be suf-
ficient to recruit two general practices, but up to five will
be recruited to increase generalisability.
Methods of data analysis
The data will be used to scope the extent and patterns of
current cancer-related self-test use and produce profiles of
the people who use or would use self-testing for cancer.BMC Cancer 2006, 6:215 http://www.biomedcentral.com/1471-2407/6/215
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Participants will be classified according to their use of self-
test kits related to cancer. Estimates of the prevalence of
the use of self-testing for cancer will be determined after
appropriate standardisation to the England and Wales
population.
The characteristics of those who have used a self-test kit
will be estimated by discriminant analysis. This multivar-
iate technique classifies individuals to known groups on
the basis of known information on the individual (e.g.
age, gender, Townsend score). The characteristics of
patients who have accessed self-testing will be compared
with those who have not. The model will aim to identify
the predictors of self-test kit use. Logistic regression anal-
ysis will be utilised.
Bias and confounding
The questionnaire will be piloted to ensure readability,
comprehension, and acceptability. Participation com-
prises the completion of a short postal questionnaire. We
have kept demands on participants to a minimum to max-
imise compliance and minimise selection bias.
Given the study design (i.e. unsolicited requests for infor-
mation), it is inevitable that there will be a significant
minority of individuals in the sample who do not
respond. In addition, it seems likely that those who do
respond will be different in important respects to those
who do not. Estimates of response rates by age, sex and
deprivation score will be made and standardised preva-
lence rates will be calculated to overcome some of the
potential bias.
Ethical approval
This study has been approved by Solihull Local Research
Ethics Committee, reference 05/Q2706/13.
Discussion
Cancer related self-tests, currently available from pharma-
cies or over the Internet, include FOB kits (related to
bowel cancer), PSA tests (related to prostate cancer),
breast cancer kits (self-examination guide) and haematu-
ria tests (related to urinary tract cancers) [57]. The range of
available tests is likely to increase in the near future. The
effect of such an escalation in self-testing for cancer is
unknown but may be considerable: it may affect the deliv-
ery of population based screening programmes; empower
patients or cause unnecessary anxiety; reduce costs on
existing healthcare services or increase demand to investi-
gate patients with positive test results. It is important that
more is known about the characteristics of those who are
using self-tests if we are to determine the potential impact
on health services and the public.
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